new glp 1 receptor agonists GLP-1 and next-generation metabolic hormone therapies in chronic kidney disease Glucagon-like peptide-1 receptor: mechanisms and

FDA Adverse Event Reporting System (FAERS), spanning from Q1 2004 to Q1 2024

It plays several important roles: Helping maintain healthy blood sugar levels after meals Supporting a feeling of fullness and satisfaction Regulating appetite and digestion When GLP-1 activity is healthy, it may help reduce cravings, support balanced energy, and contribute to gradual, sustainable weight management

CU Cancer Center member Bryan Haugen, MD, breaks down the science behind the FDA warning on the GLP-1 weight-loss medications.

The development of long-acting incretin receptor agonists represents a significant advance in the fight against the concurrent epidemics of type 2 diabetes mellitus (T2DM) and obesity

Furthermore,...